Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

NOT YET RECRUITING

NCT07232199

Clinical Investigation of Sensovisc Sterile Sodium Hyaluronate Gel

Sponsor: Ankara City Hospital Bilkent

View on ClinicalTrials.gov

Summary

This clinical investigation aims to investigate the safety and performance of Sensovisc.Sensovisc is used to reduce osteoarthritis related pain in the joints by supporting synovial fluid by intra-articular injection and allowing the synovial fluid to restore its viscoelastic properties. It increases the joint mobility by reducing or eliminating the pain.

Official title: Clinical Investigation of Sensovisc Sterile Sodium Hyaluronate Gel in the Hip Joint

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

Start Date

2025-11-25

Completion Date

2026-11-25

Last Updated

2025-11-18

Healthy Volunteers

Conditions

Osteoarthritis

Interventions

DEVICE

SV-3-75: Sterile Sodium Hyaluronate Gel-3 mL Prefilled Syringe (2.5%)

Sensovisc is used to reduce osteoarthritis related pain in the joints by supporting synovial fluid by intra-articular injection and allowing the synovial fluid to restore its viscoelastic properties. It increases the joint mobility by reducing or eliminating the pain. It will be injected in hip joint in this investigation. The injection will be administered under fluoroscopic and ultrasound guidance.

Inclusion Criteria: * \>18 years old * Patients who have unilateral and/or bilateral hip pain for more than 3 months and meet the diagnosis of coxarthrosis according to ACR criteria * 40 mm above the pain level determined by the Visual Analogue Scale (VAS) during rest for at least 15 days in the month before starting the study (for paracetamol and oral NSAIDs, taking into account the half-life of the drug). * Diagnosis of hip osteoarthritis with Stage II or III according to the Kellgren and Lawrence (KL) classification, as determined by x-rays taken in the last 12 months * Ambulating with or without support * Having the mental ability to express pain scores * Signing the informed consent form indicating consent to participate in the study Exclusion Criteria: * Radiological Kellgren-Lawrence (K\&L) stage I or IV * Other non-degenerative causes of hip pain * septic arthritis * Avascular necrosis, * Femoroacetabular impingement syndrome, * Trochanteric bursitis * Having a history of lower extremity fracture/surgery within the last 6 months * Pregnancy, breastfeeding, pregnancy plan * Morbidly obese patients (BMI\>40), * Patients with unstable medical conditions (liver or kidney failure, lung/heart disease, tumor, HIV, etc.) * Known central nervous system and/or peripheral nervous system disease * When fluoroscopy guided injection is contraindicated: * pregnancy, * contrast material allergy, * local anesthetic allergy, * Having conditions such as coagulopathy * Related to Treatment * Corticosteroid injection into the target joint within the last 1 month before the first injection * Hyaluronan injection into the target joint within the last 6 months before the first injection * Arthroscopy or surgery on the target joint within the last 6 months before the first injection * Those who use blood thinners (warfarin compounds and heparin) or have bleeding problems * Contraindications for SENSOVISC: Hypersensitivity to product ingredients, systemic infection, presence of local infection on the buttocks, infection or skin disease at the injection site or joint area